Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, initially developed for lipid-lowering therapy in patients with hypercholesterolemia, were recently investigated for their potential role in cancer prevention [179]. This evidence concerns the gene PCSK9 and cancer.